reports
Nanobiotix: 1 director
A director at Nanobiotix bought 1,100 shares at 26.618USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Charlotte Vaisse
- Equipe Sustainability
- Luis de Toledo Heras
- Marc Lavaud
VLS VALNEVA SE
BAMNB KONINKLIJKE BAM GROEP NV
NEX NEXANS SA
ERA ERAMET SA
VID VIDRALA SA
KRN KRONES AG
CARM CARMILA SAS
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
SHOT SCANDIC HOTELS GROUP
SAFE SAFESTORE HOLDINGS PLC
VGP VGP NV
BRAV BRAVIDA HOLDING AB
FTG111 FLATEXDEGIRO AG
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
2CRSI 2CRSI SA
AZE AZELIS GROUP NV
AF AIR FRANCE - KLM
LOCAL SOLOCAL GROUP
- Charlotte Vaisse
- Equipe Sustainability
- Luis de Toledo Heras
- Marc Lavaud
VLS VALNEVA SE
BAMNB KONINKLIJKE BAM GROEP NV
NEX NEXANS SA
ERA ERAMET SA
VID VIDRALA SA
KRN KRONES AG
CARM CARMILA SAS
IRES IRISH RESIDENTIAL PROPERTIES REIT PLC
SHOT SCANDIC HOTELS GROUP
SAFE SAFESTORE HOLDINGS PLC
VGP VGP NV
BRAV BRAVIDA HOLDING AB
FTG111 FLATEXDEGIRO AG
TKO TIKEHAU CAPITAL SCA
DUE DURR AG
2CRSI 2CRSI SA
AZE AZELIS GROUP NV
AF AIR FRANCE - KLM
LOCAL SOLOCAL GROUP
- Martial Descoutures
- Martial Descoutures
Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 20...
Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 2025; gibt einen Ausblick für 2026 Gesamtumsatz von 174,7 Millionen Euro im Rahmen der Prognose, davon 157,9 Millionen Euro aus Produktumsatz Starke Liquiditätsposition zum Jahresende in Höhe von 109,7 Millionen Euro, mit verbesserter finanzieller Flexibilität nach erfolgreicher Umschuldung 2026 könnte ein Jahr des Wandels werden, da in der ersten Jahreshälfte Daten zur Phase 3 der Lyme-Borreliose-Studie erwartet werden Der Vertrag des Chief Executive Officers wurde um weitere drei Jahre verlängert, wodurch die Kontinuität...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provid...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – (Nasdaq: VALN; Euronext Paris...
Valneva publie son chiffre d’affaires et sa trésorerie non audités pou...
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2025 et fournit ses prévisions pour l’exercice 2026 Chiffre d’affaires de 174,7millions d’euros en ligne avec les prévisions, dont 157,9 millions d’euros de ventes de vaccinsSolide position de trésorerie de 109,7 millions d’euros à fin 2025 et flexibilité financière renforcée suite au refinancement réussi de la dette 2026 pourrait être une année transformatrice pour Valneva, avec des données de Phase 3 sur le vaccin Lyme attendues au premier semestre.Mandat du Directeur Général de Valneva renouvelé pour une...
Information mensuelle relative au nombre total de droits de vote et d...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 17 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable231 janvier 202648 450 35850 153 46050 131 342 À pr...
Voting Rights and Shares Capital of the Company
Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisable2January 31, 202648,450,35850,153,46050,131,342 About NANOBIOTI...
Voltalia: 1 director
A director at Voltalia sold 18,200 shares at 7.182EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Voltalia SA: Total number of shares and voting rights in the share cap...
Voltalia SA: Total number of shares and voting rights in the share capital as of January 31, 2026 Total number of shares and voting rights in the share capital as of January 31, 2026 (Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) Date Total number of shares in the capital Number of theoretical voting rights Number of exercisable voting rights 01/31/2026 131 318 716223 407 839223 021 449 Next on the agenda: 2025 full year results, on March 12, 2026 (before market opening) About Voltalia ()Voltalia is a...
Voltalia SA : Nombre total de droits de vote et d’actions composant le...
Voltalia SA : Nombre total de droits de vote et d’actions composant le capital en date du 31 janvier 2026 Nombre total de droits de vote et d’actions composant le capital en date du 31 janvier 2026 (Art. L. 233-8 (II) du Code de Commerce et Art. 223-16 du Règlement Général de l’AMF) Date Nombre d’actions composant le capitalNombre de droits de vote théoriquesNombre de droits de vote exerçables31/01/2026 131 318 716223 407 839223 021 449 Prochain rendez-vous : Résultats annuels 2025, le 12 mars 2026 (avant bourse) A propos de Voltalia ()Voltalia est un acteur i...
Renvolt, la nouvelle filiale de Voltalia dédiée aux Services, signe un...
Renvolt, la nouvelle filiale de Voltalia dédiée aux Services, signe un nouveau contrat de construction en Irlande Renvolt, la nouvelle filiale de Voltalia dédiée aux Services, signe un nouveau contrat de construction en Irlande Voltalia (Euronext Paris, ISIN code : FR0011995588), acteur international des énergies renouvelables, et Renvolt, sa filiale dédiée aux Services de construction et de maintenance, annoncent la signature d’un contrat clé en main d’ingénierie, d’approvisionnement et de construction (EPC) pour la réalisation du projet Wexford Hub, une centrale solaire de 124,2 mégawatt...
Renvolt, Voltalia's new subsidiary dedicated to Services, signs a new ...
Renvolt, Voltalia's new subsidiary dedicated to Services, signs a new construction contract in Ireland Renvolt, Voltalia's new subsidiary dedicated to Services, signs a new construction contract in Ireland Voltalia (Euronext Paris, ISIN code: FR0011995588), an international renewable energy player, and Renvolt, its subsidiary dedicated to construction and maintenance services, announce the signing of a turnkey engineering, procurement and construction (EPC) contract for ESB Wexford Hub project, a 124.2-megawatt solar power plant This contract, signed by Renvolt, strengthens the collaborat...
Valneva fait un point sur l’utilisation du vaccin IXCHIQ® au Royaume-...
Valneva fait un point sur l’utilisation du vaccin IXCHIQ® au Royaume-Uni Lyon (France), le 13 février 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’à la suite d’une revue des bénéfices et risques du vaccin contre le chikungunya de la société, IXCHIQ®, la Commission britannique des médicaments à usage humain (CHM) a mis à jour ses recommandations concernant l’utilisation de ce vaccin. Les informations de prescription (PI) mises à jour refléteront ces recommandations, qui incluent désormais une restriction pour les personnes de...
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the U...
Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom Lyon (France), February 13, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company’s single‑dose chikungunya vaccine, IXCHIQ®, the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine. The updated Prescribing Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for people with sp...
VALNEVA Declaration of shares and voting rights: January 31, 2026
VALNEVA Declaration of shares and voting rights: January 31, 2026 VALNEVA Declaration of shares and voting rights January 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: correction as of February 11, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change D...
VALNEVA Déclaration d’actions et de droits de vote : 31 janvier 2026
VALNEVA Déclaration d’actions et de droits de vote : 31 janvier 2026 VALNEVA Déclaration d’actions et de droits de vote 31 janvier 2026__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Marché réglementé Euronext Paris - Compartiment B Date de la déclaration : correctif au 11 février 2026 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origin...
DBV Technologies to Present Additional Data from the VITESSE Phase 3 S...
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.